Oruka's Psoriasis Drug Repeats Strong Clearance in Phase 2

Oruka Therapeutics produced a second strong Phase 2 result for ORKA-001, its experimental treatment for moderate-to-severe plaque psoriasis. In the high-dose group of the EVERLAST-B study, 61% of patients achieved completely clear skin at week 16, compared with none of the placebo patients.

The result met the trial's primary endpoint with a p-value below 0.0001. In the same high-dose group, 86% of patients achieved at least a 90% improvement in the Psoriasis Area and Severity Index, known as PASI 90, and 86% reached an Investigator's Global Assessment score of clear or almost clear.

EVERLAST-B enrolled 187 patients across 36 sites in the United States, Canada and Europe. Participants were randomized equally among placebo and three ORKA-001 doses. The high-dose arm included 46 patients who received 600 milligrams at weeks zero and four. The study will continue through week 100 to examine durability, maintenance dosing and longer-term safety.

The consistency with Oruka's earlier EVERLAST-A study is the main reason the data matter. That trial reported a 63% PASI 100 rate for the comparable high-dose group at week 16. Repeating a similar result in a separate trial reduces the chance that the first result was an isolated outcome, although both studies remain company-sponsored Phase 2 programs.

Safety was favorable through week 16. Thirty-nine percent of high-dose patients experienced at least one treatment-emergent adverse event, compared with 43% on placebo. No serious or severe adverse events occurred in the high-dose group, and no injection-site reactions were reported among ORKA-001 recipients.

Oruka's proposed commercial advantage is infrequent dosing. The company is testing whether patients who reach complete clearance can maintain the response with one or two doses per year. Existing IL-23 psoriasis drugs are generally administered more often. The comparison is strategically important, but it remains unproven until longer follow-up shows that the response lasts.

The company expects 52-week EVERLAST-A data in December 2026 and plans to begin Phase 3 trials in the first half of 2027, subject to discussions with regulators. Oruka had about $1.1 billion in cash, cash equivalents and marketable securities at June 30. That balance supports development, but Phase 3 trials will increase spending and the company has no commercial product revenue.

The stock's positive reaction reflects both replication and the possibility of a more convenient dosing schedule. Investors should avoid treating the 61% result as a direct head-to-head win over AbbVie's Skyrizi or Johnson & Johnson's Tremfya. Oruka's comparison with approved drugs uses separate trials with different patients and designs. The next value-changing evidence is durability at 52 weeks, followed by successful Phase 3 replication and regulatory review.